| Literature DB >> 35631337 |
Xabier Del Corte1, Adrián López-Francés1, Ilia Villate-Beitia2,3,4, Myriam Sainz-Ramos2,3,4, Edorta Martínez de Marigorta1, Francisco Palacios1, Concepción Alonso1, Jesús M de Los Santos1, José Luis Pedraz2,3,4, Javier Vicario1.
Abstract
We report efficient synthetic methodologies for the preparation of 3-amino and 3-hydroxy 3-pyrrolin-2-ones (unsaturated γ-lactams) through a multicomponent reaction of amines, aldehydes and acetylene or pyruvate derivatives. The densely substituted γ-lactam substrates show in vitro cytotoxicity, inhibiting the growth of the carcinoma human tumor cell lines RKO (human colon epithelial carcinoma), SKOV3 (human ovarian carcinoma) and A549 (carcinomic human alveolar basal epithelial cell). In view of the possibilities for the diversity of the substituents that offer a multicomponent, synthetic methodology, an extensive structure-activity profile is presented. In addition, the bioisosteric replacement of the flat ester group by a tetrahedral phosphonate or phosphine oxide moiety in γ-lactam substrates leads to increased growth inhibition activity. Cell morphology analysis and flow cytometry assays indicate that the main pathway by which our compounds induce cytotoxicity is based on the activation of the intracellular apoptotic mechanism.Entities:
Keywords: antiproliferative activity; bioisosterism; multicomponent synthesis; phosphine oxides; phosphonates; γ-lactams
Year: 2022 PMID: 35631337 PMCID: PMC9144317 DOI: 10.3390/ph15050511
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Relevant γ-lactam-containing structures.
Scheme 1Multicomponent synthesis of 3-amino 3-pyrrolin-2-ones 4.
Figure 23-Amino 3-pyrrolin-2-ones 4, 8 and 9 obtained.
Figure 33-Hydroxy 3-pyrrolin-2-ones 12 obtained.
Figure 43-Hydroxy 3-pyrrolin-2-ones 13 obtained.
Antiproliferative activity of 3-amino γ-lactam derivatives 4, 8 and 9.
| Entry | Cmpd. | IC50 (μM) | ||
|---|---|---|---|---|
| A549 (Lung) | SKOV3 (Ovarian) | MRC5 | ||
| 1 |
| 11.70 ± 1.02 | >50 | >50 |
| 2 |
| 14.26 ± 1.80 | >50 | >50 |
| 3 |
| 2.42 ± 0.15 | >50 | >50 |
| 4 |
| 3.34 ± 0.29 | 48.45 ± 2.90 | >50 |
| 5 |
| 1.67 ± 0.49 | >50 | >50 |
| 6 |
| 42.58 ± 2.55 | 30.27 ± 1.03 | >50 |
| 7 |
| 7.64 ± 0.17 | >50 | >50 |
| 8 |
| 1.98 ± 0.18 | 10.37 ± 1.41 | 10.01 ± 1.79 |
| 9 |
| 10.71 ± 1.35 | 21.91 ± 1.53 | 17.37 ± 1.68 |
| 10 |
| 13.03 ± 1.48 | 43.93 ± 1.66 | 30.93 ± 6.16 |
| 11 |
| 11.39 ± 1.49 | >50 | >50 |
| 12 |
| 0.11 ± 0.016 | 1.23 ± 0.31 | 12.64 ± 2.09 |
| 13 |
| 6.02 ± 1.01 | >50 | >50 |
| 14 |
| 2.97 ± 0.29 | 6.95 ± 0.59 | >50 |
| 15 |
| 32.38 ± 1.58 | 16.62 ± 0.19 | 21.42 ± 2.7 |
| 16 |
| 12.45 ± 0.71 | >50 | >50 |
| 17 | Doxorubicin | <0.1 | 0.13 ± 0.098 | >50 |
Antiproliferative activity of 3-hydroxy γ-lactam derivatives 13.
| Entry | Cmpd. | IC50 (μM) | ||
|---|---|---|---|---|
| A549 (Lung) | SKOV3 (Ovarian) | MRC5 | ||
| 1 |
| 15.73 ± 1.27 | >50 | >50 |
| 2 |
| 13.05 ± 0.56 | >50 | >50 |
| 3 |
| 4.50 ± 0.18 | >50 | >50 |
| 4 |
| 19.13 ± 3.00 | >50 | >50 |
| 5 |
| 17.64 ± 3.76 | >50 | >50 |
| 6 |
| 15.96 ± 1.97 | >50 | >50 |
| 7 |
| 13.30 ± 2.19 | 10.36 ± 0.35 | >50 |
| 17 | Doxorubicin | <0.1 | 0.13 ± 0.098 | >50 |
Antiproliferative activity of 3-hydroxy γ-lactam derivatives 12.
| Entry | Cmpd. | IC50 (μM) | ||
|---|---|---|---|---|
| A549 (Lung) | SKOV3 (Ovarian) | MRC5 | ||
| 1 |
| 3.11 ± 0.31 | >50 | >50 |
| 2 |
| 4.56 ± 0.44 | >50 | >50 |
| 3 |
| 16.03 ± 1.49 | >50 | >50 |
| 4 |
| >50 | >50 | n.d. |
| 5 |
| 6.60 ± 0.58 | >50 | >50 |
| 6 |
| 23.29 ± 2.40 | >50 | >50 |
| 7 |
| 8.27 ± 0.91 | >50 | >50 |
| 8 |
| 24.20 ± 0.81 | >50 | >50 |
| 9 |
| 5.36 ± 0.28 | 11.56 ± 3.36 | >50 |
| 10 |
| 5.91 ± 0.69 | 15.55 ± 1.60 | >50 |
| 11 |
| >50 | >50 | n.d. |
| 12 |
| 11.86 ± 1.35 | >50 | >50 |
| 13 |
| 3.72 ± 0.32 | >50 | >50 |
| 14 |
| 5.50 ± 1.35 | >50 | >50 |
| 15 |
| 1.46 ± 0.19 | 21.97 ± 3.42 | >50 |
| 16 |
| 20.34 ± 0.79 | >50 | >50 |
| 17 | Doxorubicin | <0.1 | 0.13 ± 0.098 | >50 |
n.d. = not determined.
Figure 5Percentages of early apoptotic (green bars) and late apoptotic (orange bars) A549 cells 24 h after exposure to compounds 4l (1 µM) and 12a (5 µM). Each value represents the mean ± SD of 3 measurements.
Figure 6Cell morphology visualization with an X4 lens at 0, 1, 6, 12, 24, 48 and 72 h after exposure to compound 4l. Scale bar: 300 µm. (A) A549 cells treated with 1.1 µM of 4l. (B) A549 cells treated with 0.11 µM of 4l. (C) A549 cells treated with 0.02 µM of 4l.